Scholar Rock Holding
Scholar Rock Holding Corp is an American clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting muscle and bone diseases. The company utilizes its proprietary discovery platform to target growth factor activation mechanisms, specifically focusing on myostatin inhibition for rare and severe conditions. Its leading clinical pipeline candidate is apitegromab, being evaluated for the treatment of spinal muscular atrophy and other neuromuscular disorders. Core operations encompass preclinical drug design, protein engineering, clinical trial management, and biotechnology research. As a development-stage biopharmaceutical entity, the company generates minimal commercial revenue and relies on equity financing and research partnerships. Scholar Rock is headquartered in Cambridge, Massachusetts, United States, and its common stock trades on the Nasdaq Global Market.
7 of the funds FundTelligence covers report a position in Scholar Rock Holding.
- Legal name
- Scholar Rock Holding Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding Scholar Rock Holding
- DNB Bioteknologi — DNB · 2.58 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 1.17 % (full portfolio disclosed, June 2026)
- BNP US Small Cap — BNP Paribas · 1.05 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.37 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)